Key facts
- This page summarizes Christine D. Baker's Form 4 filing for TYME TECHNOLOGIES, INC..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 16 Sep 2022, 18:00.
Christine D. Baker - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 16 Sep 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Sep 2022, 18:00:31 UTC
- Prior SEC filing
- 29 Aug 2022
- Next SEC filing
- 18 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Richard Cunningham as attorney-in-fact for Christine D. Baker
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christine D. Baker filed Form 4 for TYME TECHNOLOGIES, INC. on 16 Sep 2022.
Change
- Previous filing in this sequence was filed on 29 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TYME
transaction
Derivative
Director Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -14,666
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,666
- Exercise price
- $0.3500
- Footnotes
- F1
TYME
transaction
Derivative
Director Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -36,888
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 36,888
- Exercise price
- $0.3500
- Footnotes
- F2
TYME
transaction
Derivative
Director Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -88,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 36,888
- Exercise price
- $0.3100
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Christine D. Baker is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
This award consisted of options to purchase 176,000 shares of Tyme common stock, 14,666 of which had vested as of the date of the merger between the issuer and Syros Pharmaceuticals, Inc ("Syros"). The vested portion was assumed by Syros in the merger and replaced with an option to purchase 642 shares of Syros common stock for $7.99 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"). The remaining unvested portion of the option award was cancelled upon the reporting person's resignation from the board in connection with the merger, pursuant to the terms of the award.
Footnote F2
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,616 shares of Syros common stock for $7.99 per share, after giving effect to the Reverse Split.
Footnote F3
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.